
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
The American Journal of Managed Care
over 25 years ago
Does the HEDIS Asthma Measure Go Far Enough?over 25 years ago
Rheumatoid Arthritis: Guidelines for Emerging Therapies





